Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01931566 · ClinicalTrials.gov registry record · Phase 3
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Phase 3 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3,494
- Enrollment target
NCT01931566 is a Phase 3 study that was terminated before completion, run by Takeda. The registered enrollment target is 3,494 participants.
The verdict
NCT01931566, a Phase 3 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3,494 participants
- Enrollment target
Study Summary
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone compared with placebo to delay the onset of MCI-AD in cognitively-normal participants who are at high-risk for developing MCI within 5 years.
Interventions
- DRUG Pioglitazone
- DRUG Pioglitazone placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,494 participants |
| Start Date | 2013-08-01 |
| Est. Completion | 2018-09-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01931566
The ClinicalTrials.gov registry entry for NCT01931566 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3,494 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone is the first listed.
NCT01931566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01931566 about?
NCT01931566 is a clinical study titled "Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset". The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone compared with placebo to delay the onset of MCI-AD in cognitively-normal parti...
What is the current status of trial NCT01931566?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3,494 participants. The study started on 2013-08-01. Estimated completion is 2018-09-06.
What interventions are being tested in trial NCT01931566?
The interventions under investigation include: Pioglitazone (DRUG), Pioglitazone placebo (DRUG).
Who is sponsoring clinical trial NCT01931566?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.